熱門資訊> 正文

Artiva Biotherapeutics GAAP每股收益为-22.00美元

2024-08-30 04:25

Artiva Biotherapeutics, Inc.(ARTV) 0
Lineage(LINE) 0

Artiva Biotherapeutics press release (NASDAQ:ARTV): Q2 GAAP EPS of -$22.00.
As of June 30, 2024, Artiva had cash, cash equivalents, and short-term investments of $46.6 million. In addition, Artiva completed its IPO in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option, for gross proceeds of $179.0 million.

More on Artiva Biotherapeutics

Artiva: Natural Killer Cell Biotech With First Half Of 2025 Lupus Treatment Data
IPO Roundup: Lineage, OneStream Software, and more
Artiva Biotherapeutics surges on trading debut
Historical earnings data for Artiva Biotherapeutics
Financial information for Artiva Biotherapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。